Researchers at Mass General Brigham discovered that using sodium-glucose contratransporter 2 (SGLT2) inhibitors was associated with a decreased chance of acquiring kidney stones. Their findings were published in JAMA Internal Medicine.
Patients with and without diabetes can benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are drugs that, among other things, reduce blood sugar levels and improve heart and kidney function.
Washington [US], May 27 (ANI): Sodium-glucose transporter-2 (SGLT2) inhibitors, which reduce renal glucose reabsorption, may help control blood sugar and protect kidney health in patients with diabetic renal failure; however, several large clinical trials have linked these drugs to a higher
Mumbai (Maharashtra) [India], October 26 (ANI): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed drug combination for the management of type 2 diabetes.
Washington [US], September 28 (ANI): Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.